Executives from Contineum Therapeutics (NASDAQ:CTNM) outlined the company’s clinical priorities and upcoming catalysts during a presentation at the Leerink Global Healthcare Conference, emphasizing a shift from a discovery platform to a clinical-stage company with two lead programs and multiple trials underway. Strategy: From platform to clinical-stage focus CEO Carmine Stengone described Contineum as a small-molecule […]